Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.

Journal of neuro-oncology - 1 Dec 2022

Svenjeby Caroline, Carstam Louise, Werlenius Katja, Bontell Thomas Olsson, Rydén Isabelle, Jacobsson Julia, Dénes Anna, Jakola Asgeir S, Corell Alba

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase (IDH) mutated diffuse lower-grade gliomas (dLGG) are infiltrating brain tumors and increasing evidence is in favor of early multimodal treatment. In a Scandinavian population-based setting, we wanted to study treatment patterns over the last 15 years, focusing on the short-term postoperative course to better understand the potential negative consequences of treatment. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Postoperative Period

Source

Open in PubMed Open full text

Identifiers

PMID: 36434487
DOI: 10.1007/s11060-022-04136-y
PMCID: PMC9758083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.PMID 36434487Read ↗

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.Semantic proximity Read ↗

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Diagnostic Approaches to Adult-Type Diffuse Glial Tumors: Comparative Literature and Clinical Practice Study.Semantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

Congress of Neurological Surgeons Systematic Review and Evidence-based Guidelines Update on the Role of Neuropathology in the Management of Progressive Glioblastoma in AdultsSemantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.Semantic proximity Read ↗

Neuro-oncology Treatment Strategies for Primary Glial Tumors.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.